Product Info: White Papers

AeronebGO would like to welcome all providers, and thank you for your interest in the Aeroneb GO as a treatment.

Does Use of a Nebulizer Result in an Increase in Drug Concentration?

Increasing residual drug concentration during the process of ultrasonic nebulization has been identified, but has not been well defined with pneumatic nebulizers, or the novel Aeroneb™ Portable Nebulizer System.
 

Pharmacy Services of America: Physicians Section

Metered-dose inhalers help only if you know how to use them. "It takes a certain amount of coordination and skill to use a metered-dose inhaler properly," says James T. Li, MD, a specialist in asthma, allergy and immunology at Mayo Clinic, Rochester, MN. "Many surveys show that most people who use the MDI, maybe up to two-thirds, use it improperly."

Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System

Cystic fibrosis (CF) patients with endobronchial infections caused by Pseudomonas aeruginosa are customarily treated with two parenteral antipseudomonal antibiotics, one of which is typically an aminoglycoside.

Does Reduced Dose Volume Impact Inhaled Mass With a Novel Low Residual Volume Nebulizer?

Standard jet and ultrasonic nebulizers leave residual drug volumes in their medication reservoirs ranging from 0.8 to 2.0 mL at the end of therapy. (Hess et al., Chest 1998). These nebulizers have been shown to be more efficient as drug volume placed in the medication reservoir is increased.

Budesonide Administration With a Novel Aerosol Generator: An In Vitro Evaluation

Budesonide (Pulmicort® Respules®, Astra USA) is approved for use with pneumatic jet nebulizers which deliver from 2 to 18% drug mass of the nominal charge. Ultrasonic nebulizers have been shown to be inefficient in nebulizing suspensions.

In Vitro Comparison of a Novel nebulizer With Ultrasonic and Pneumatic Nebulizers

Nebulizers vary in the amount of inhaled drug and the time required to administer a treatment. The lower the inhaled dose and the longer the time of administration, the less likely the patient will be to adhere to the prescribed treatment plan.

Bronchodilator Response to Ipratropium Delivered Via Aerodose® Inhaler or Pari LC Plus™ Nebulizer in COPD Patients

Chronic obstructive pulmonary disease (COPD) is characterized by a slow deterioration of lung function and progressive breathlessness with activity.

Gamma Scintigraphy Lung Deposition Comparison of Tobi® in the Pari LC Plus™ Nebulizer and the Aerodose™ Inhaler

Cystic fibrosis (CF) is a genetic disease that primarily affects people of Caucasian origin. Patients with CF typically suffer from chronic respiratory infections as a result of bacterial infection of their airways. Such chronic lung infections cause gradual destruction of lung tissue, leading to progressive lung disease and eventually, respiratory failure.

In Vitro Comparison of an Electronic Micropump Nebulizer With Other High Efficiency Nebulizers

Commercially available nebulizers span a broad range of performance parameters. The performance of high efficiency nebulizer models were characterized using albuterol sulfate inhalation solution to det ermine aerosol output (flow) rate, residual drug volume, inhaled dose using simulated adult tidal breathing, aerosol particle size by laser diffraction, and aerosol particle size
distribution by cascade impactor.